Is a reduction in albuminuria associated with renal and cardiovascular protection? A post‐hoc analysis of the ALTITUDE trial

ConclusionsAddition of aliskiren to ACEi/ARB therapy shows albuminuria changes that are associated with renal and cardiovascular risk changes. This did not translate into renal or cardiovascular protection since the overall albuminuria reduction in the aliskiren arm was too small and nearly similar to placebo.

Source: Diabetes, Obesity and Metabolism - October 30, 2015 Category: Endocrinology Authors: Hiddo J. Lambers Heerspink, Toshiharu Ninomiya, Frederik Persson, Barry M. Brenner, Patrick Brunel, Nish Chaturvedi, Akshay S. Desai, S.M. Haffner, John J.V. Mcmurray, Scott D. Solomon, Marc A. Pfeffer, Hans‐Henrik Parving, Dick de Zeeuw Tags: ORIGINAL ARTICLE Source Type: research